Search - tctmd.com

Displaying 301 - 320 of 492

Sort: Relevancy | Date

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2015

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

Caitlin E. Cox

August 31, 2015

News Daily News

CAD Location May Influence Need for Prolonged DAPT Post-PCI

Caitlin E. Cox

August 24, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Yael L. Maxwell

July 29, 2015

News Industry News

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

July 23, 2015

News Industry News

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

July 16, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

News Industry News

UK launch for Daiichi's bloodthinner Lixiana

July 10, 2015

News Daily News

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

Yael L. Maxwell

July 10, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Daily News

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

Todd Neale

June 29, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Industry News

FDA approves new antiplatelet drug used during heart procedure

June 24, 2015

News Daily News

比伐卢定加 GPI 可减少接受 PCI 的心衰患者的出血和死亡率

June 09, 2015

Advertisement

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Analyses Suggest Prasugrel Causes No Excess Bleeding in Stable CAD Patients

CAD Location May Influence Need for Prolonged DAPT Post-PCI

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

BASKET-PROVE Substudy: DES Better Than BMS in Elderly Patients With Large Arteries

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

UK launch for Daiichi's bloodthinner Lixiana

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

FDA Approval of Cangrelor Expands Antiplatelet Options for PCI

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

FDA approves new antiplatelet drug used during heart procedure

比伐卢定加 GPI 可减少接受 PCI 的心衰患者的出血和死亡率

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content